Abstract 1070P
Background
Immune checkpoint inhibitors (ICIs) have yielded promising results in the treatment of cancer patients with central nervous system (CNS) metastases. However, due to a dearth of clinical research, it is necessary to further elucidate the side effects of ICIs in patients with CNS metastases.
Methods
We identified patients with CNS metastases treated with ICIs from Q1 2013 to Q2 2022 by scrutinizing the FDA Adverse Event Reporting System (FAERS) database. Following removal of duplicate data, the study collected 511 cases. Subsequently, disproportionality analysis was performed. Risk factors were explored using univariate and multivariate logistic regression. Moreover, the influence of clinical factors on the time to onset of adverse reactions was examined.
Results
The study revealed a higher susceptibility to psychiatric complications, including confusion state, insomnia, mania, and memory impairment, following ICIs treatment in CNS metastasis patients. Furthermore, rare but severe retinal detachment may arise due to anti-PDL1 drug usage, whereas co-administration of anti-PD1 and anti-CTLA4 drugs may produce nephrotoxicity concerns. Multivariate logistic regression analysis demonstrated that the combined therapy of anti-PD1+anti-CTLA4 therapy was an independent risk factor for adverse nephrotoxic reactions in CNS metastasis patients (OR: 2.75, 95%CI: 1.37-5.46, P<0.05). The onset time of complications differed depending on the immunotherapeutic strategy. Anti-PD-L1 therapy had a later onset time of complications (Median: 67 days, IQR: 28.75-114.25) compared to that of anti-PD1 (Median: 33 days, IQR: 10-90) and anti-CTLA4 therapy (Median: 29 days, IQR:10.5-52.5), respectively. Furthermore, our study indicated that younger patients exhibited a higher probability of fatal complications (OR: 0.97, 95%CI: 0.95-0.99, P=0.02) and experienced a shorter time to onset of complications (r=2.27, P=0.007).
Conclusions
This study employed a massive database to investigate the spectrum of adverse reactions resulting from ICIs therapy administered to CNS metastasis patients, thereby providing vigilance data for broader clinical applications.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Peng Luo.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1057P - Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Presenter: Jian Li
Session: Poster session 19
1058P - Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer
Presenter: Hsiu-Tzu Wang
Session: Poster session 19
1059P - Tertiary lymphoid structures localization and maturation heterogeneities correlate with divergent clinical outcomes and immune responses of clear cell renal cell carcinoma
Presenter: Dingwei Ye
Session: Poster session 19
1061P - Association of transcriptomic mapping of tumors with high expression of Tregs to identify surfaceome gene signatures with efficacy to check point inhibitors
Presenter: María Del Mar Noblejas Lopez
Session: Poster session 19
1062P - Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Presenter: Christophe Tournigand
Session: Poster session 19
1063P - Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors
Presenter: Caterina Tozzi
Session: Poster session 19
1065P - Prospective assessment of nutritional status in patients with advanced non-small cell lung cancer and renal cell carcinoma treated with immune checkpoint inhibitors
Presenter: Federica Pecci
Session: Poster session 19
1066P - Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent
Presenter: Víctor Albarrán
Session: Poster session 19
1067P - The interchangeability of Immune checkpoint inhibitors
Presenter: Lonneke Timmers
Session: Poster session 19